Venom to medicine: the peptide drugs that began as toxins
Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board
- Exenatide, the first GLP-1 drug, is a synthetic copy of a peptide from Gila monster secretions.
- Ziconotide, a synthetic cone snail peptide given into the spinal fluid, reduced severe chronic pain in trials, with frequent neurological side effects and a boxed warning.
- Eptifibatide came from pygmy rattlesnake venom; bivalirudin from leech saliva; captopril from a Brazilian pit viper.
- Each became a drug through isolation, synthesis and clinical trials; a venom origin says nothing about safety on its own.
Why venom is a good place to look
Venoms contain peptides and proteins that act on specific targets in another animal's body: a clotting receptor, an ion channel, a hormone receptor. A 2019 review calls snake venoms attractive natural sources for drug discovery, with several substances in clinical use 1.
What follows is each drug's origin, what it does, and its US approval status as read in Drugs@FDA on October 27, 2026 2.
| Drug | Came from | Status |
|---|---|---|
| Exenatide (Byetta, Bydureon) | Exendin-4, in the saliva and venom of the Gila monster | Approved 2005; all three US applications now discontinued |
| Ziconotide (Prialt) | A peptide of the fish-eating cone snail Conus magus | Approved 2004 for severe chronic pain needing intrathecal therapy |
| Eptifibatide (Integrilin) | Barbourin, from the American southeastern pygmy rattlesnake | Approved 1998; brand discontinued, generics available |
| Bivalirudin (Angiomax) | Developed, like hirudin, from the anti-clotting action of medicinal leech saliva | Approved 2000; labelled as an anticoagulant in percutaneous coronary intervention |
| Captopril | Bradykinin-potentiating peptides from the Brazilian pit viper | A small molecule, not a peptide; the starting point was the venom peptide |
The Gila monster and the GLP-1 drugs
Exenatide is synthetic exendin-4, a peptide originally isolated from the salivary secretions of the Gila monster (review by authors from its developer, Amylin Pharmaceuticals) 3, a venomous lizard of the southwestern United States and northwestern Mexico 4. Exendin-4 shares key biological properties with human GLP-1 while resisting enzymatic breakdown better 4.
In preclinical models exenatide enhanced glucose-dependent insulin secretion, suppressed inappropriately high glucagon, slowed gastric emptying, reduced body weight and enhanced satiety, and in trials both its formulations reduced blood glucose in type 2 diabetes with weight loss (review) 3. It was approved in the US as Byetta in April 2005 and as the weekly Bydureon in January 2012, and Drugs@FDA now lists all three exenatide applications (Byetta, Bydureon, Bydureon BCise) as discontinued 2. A 2026 history traces the line from that lizard to today's GLP-1 receptor agonists for obesity and metabolic disease, and notes the Gila monster's place in Navajo culture long before any of this (review) 4.
Semaglutide is not a lizard peptide: its label describes it as a GLP-1 analogue with 94% sequence homology to human GLP-1 5. The 2026 history traces how exendin-4's discovery led to the longer-acting drugs, liraglutide and semaglutide among them 4; our semaglutide guide covers those.
The cone snail and a spinal painkiller
Ziconotide is a synthetic equivalent of a peptide found in the fish-eating marine snail Conus magus, and it blocks N-type calcium channels 6. It was approved in the US in December 2004 as Prialt 2, for severe chronic pain in adults for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine 6.
The trials show both its value and its limits. In 220 patients given slow intrathecal titration, improvement in pain scores from baseline to week three was 14.7% with ziconotide against 7.2% with placebo, with dizziness, confusion, ataxia, abnormal gait and memory impairment among the significant adverse events (randomised trial) 7. In an earlier six-day inpatient trial in 255 people with non-malignant pain, using faster titration to higher doses, the mean reduction in pain score was 31.2% against 6.0% on placebo, with a considerable incidence of side effects that the authors attribute to the rapid titration and high doses; its affiliations include the drug's then developer, Elan Pharmaceuticals (randomised trial) 8.
Ziconotide is delivered into the spinal fluid by an implanted or external microinfusion device, it is a non-opioid analgesic, and its label carries a boxed warning that severe psychiatric symptoms and neurological impairment may occur 6. The two trials also show how much the measured benefit depended on the design: a 14.7% improvement over three weeks of slow titration in one, 31.2% over six days of faster titration in the other 7 8.
Snakes, clotting and blood pressure
Snake venoms act on blood, which made them a source for cardiovascular drugs. Eptifibatide is a heptapeptide derived from barbourin, a protein in the venom of the American southeastern pygmy rattlesnake, and it blocks the platelet receptor that fibrinogen uses to make platelets clump; tirofiban is a small molecule based on the structure of echistatin, a protein in the venom of the saw-scaled viper (review) 1. Eptifibatide was approved in the US in May 1998 as Integrilin; Drugs@FDA lists the brand as discontinued, with generic eptifibatide products in prescription status 2.
Captopril's story runs the other way, from peptide to pill. Bradykinin-potentiating peptides were found in the venom of the Brazilian pit viper Bothrops jararaca, and their discovery had a pivotal influence on the development of captopril, the first active-site-directed inhibitor of angiotensin-converting enzyme and a drug used worldwide for hypertension (review) 9. Captopril itself is a small molecule, not a peptide; the same review describes the venom peptides as the starting point 9.
Leeches and thrombin
Not all of these came from venom in the strict sense. Hirudin and bivalirudin were developed from the observation that the salivary extracts of medicinal leeches prevent blood from clotting; both are bivalent direct thrombin inhibitors that bind thrombin and block its enzymatic activity (review) 10. Bivalirudin was approved in the US in December 2000 as Angiomax 2; its current label is for use as an anticoagulant in patients undergoing percutaneous coronary intervention, including those with heparin-induced thrombocytopenia 11.
The same review records what came next: the antithrombotic properties of fibrinopeptide A and the crystal structure of thrombin were key to developing small-molecule active-site inhibitors such as argatroban 10.
How the Gila monster peptide was actually found
Exendin-3 had been identified in the venom of the Mexican beaded lizard as a new member of the glucagon family acting on the pancreas, which prompted a search for a similar peptide in the venom of the Gila monster, Heloderma suspectum. Exendin-4 was isolated there in 1992; it differs from exendin-3 by two amino acid substitutions and is otherwise identical, and in dispersed guinea-pig pancreatic cells natural and synthetic exendin-4 raised cAMP from concentrations as low as 100 picomolar (laboratory study) 12.
So the order of events was: a venom peptide noticed for an effect on the pancreas, a deliberate search for relatives, isolation and sequencing 12. Exendin-4 was described in 1992; exenatide, its synthetic version, was approved as Byetta in 2005 2.
Toxins that have not become drugs
Not every toxin-derived candidate has become a drug. Chlorotoxin, a scorpion peptide, was used to make a fluorescent conjugate called tumour paint, intended to let surgeons see cancer during an operation; in mouse models it outlined glioma, medulloblastoma, prostate and intestinal cancer and sarcoma (animal study) 13. The paper is from 2007, and we found no FDA application for the conjugate (tozuleristide) in Drugs@FDA on October 27, 2026 2.
What the successes have in common
Three things stand out across these drugs. Each acts on an identified target: the GLP-1 receptor, N-type calcium channels, the platelet fibrinogen receptor, thrombin, angiotensin-converting enzyme. Each medicine is a defined synthetic molecule rather than an extract of an animal. And each was tested in controlled trials: blood glucose, pain scores, coronary outcomes 3 7 1.
Exendin-4's advantage over human GLP-1 was resistance to enzymatic breakdown 4, a chemical property, not a natural one. Ziconotide's use is limited to delivery into the spinal fluid 6.
Two of these are no longer sold as brands
All three US applications for exenatide are listed as discontinued in Drugs@FDA, and Integrilin's brand is discontinued with generic eptifibatide still available 2. We did not find a regulatory statement giving reasons in either case, and a discontinuation notice records only that a company stopped marketing a product, not why.
Exenatide was the first drug of its class 3, which has since grown around it, as our semaglutide guide maps; eptifibatide's brand has been replaced by its own generics 2.
The marketing version of this story
A dramatic natural source implies neither potency nor safety. Our melanotan II entry and manufacturing guide cover compounds with no approval. The drugs above are distinguished by what happened after the discovery: isolation, synthesis, trials and labels.
The bottom line
A desert lizard's peptide led to the first GLP-1 drug; a cone snail peptide became a spinal painkiller for people other treatments have failed; a rattlesnake and a leech supplied cardiovascular drugs; a pit viper's peptides led to captopril. In each case synthesis and clinical trials came after the discovery.
Frequently asked questions
Is Ozempic made from Gila monster venom?
No. The first drug in the class, exenatide, is a synthetic copy of a Gila monster peptide; semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1.
What drug comes from cone snail venom?
Ziconotide (Prialt), a synthetic version of a Conus magus peptide, approved in 2004 for severe chronic pain in adults for whom intrathecal therapy is warranted.
Which heart drugs came from snake venom?
Eptifibatide derives from barbourin, a pygmy rattlesnake protein; tirofiban is based on echistatin from saw-scaled viper venom; and captopril was developed from pit viper peptides.
Is bivalirudin made from leeches?
It was developed from hirudin, found in medicinal leech saliva; the drug itself is synthesised.
Does a venom origin make a peptide safe or potent?
No. These drugs succeeded because they were isolated, synthesised and tested in trials, not because of their source.
Related on Grey Peptides
Sources
- Lazarovici, P., et al. (2019). From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs. Toxins (Basel), 11(5). PMID: 31137917
- U.S. Food and Drug Administration. Drugs@FDA records via openFDA: Byetta NDA 021773 (approved April 28, 2005), Bydureon NDA 022200 (January 27, 2012) and Bydureon BCise NDA 209210 (October 20, 2017), all products discontinued; Prialt NDA 021060 (December 28, 2004); Integrilin NDA 020718 (May 18, 1998), discontinued, with eptifibatide ANDA products in prescription status; Angiomax NDA 020873 (December 15, 2000); no application for tozuleristide. Read October 27, 2026. FDA
- Parkes, D. G., et al. (2013). Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov, 8(2), 219-44. PMID: 23231438
- Dyson, S., et al. (2026). From Gila Monster Venom to Dermatology: The History of GLP-1 Receptor Agonists. Clin Dermatol, . PMID: 42749027
- Wegovy (semaglutide) US prescribing information, section 12.1 (DailyMed version 19, effective June 18, 2026); read October 27, 2026. DailyMed
- Prialt (ziconotide) intrathecal infusion US prescribing information: boxed warning, sections 1, 2.1 and 11 (DailyMed version 4, effective September 15, 2026); read October 27, 2026. DailyMed
- Rauck, R. L., et al. (2006). A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage, 31(5), 393-406. PMID: 16716870
- Wallace, M. S., et al. (2006). Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation, 9(2), 75-86. PMID: 22151630
- Camargo, A. C., et al. (2012). Bradykinin-potentiating peptides: beyond captopril. Toxicon, 59(4), 516-23. PMID: 21835190
- Coppens, M., et al. (2012). Translational success stories: development of direct thrombin inhibitors. Circ Res, 111(7), 920-9. PMID: 22982873
- Bivalirudin for injection (Sandoz, holder of the Angiomax application) US prescribing information, section 1 (DailyMed version 5); read October 27, 2026. DailyMed
- Eng, J., et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem, 267(11), 7402-5. PMID: 1313797
- Veiseh, M., et al. (2007). Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res, 67(14), 6882-8. PMID: 17638899
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead